中国实验血液学杂志最新文献

{"title":"[Gene Mutation Characteristics, Prognosis and Survival Analysis of Patients with Acute Myeloid Leukemia].","authors":"Miao He, Hong-Juan Tian, Dong-Feng Mao, Xiao-Chen Zhao, Shu-Ting Zhang, Fang-Qing Zhao, Tao Wu","doi":"10.19746/j.cnki.issn.1009-2137.2025.03.010","DOIUrl":"https://doi.org/10.19746/j.cnki.issn.1009-2137.2025.03.010","url":null,"abstract":"<p><strong>Objective: </strong>To analyze the gene mutation characteristics and survival time of patients with newly diagnosed acute myeloid leukemia (AML) based on next-generation sequencing(NGS) gene detection.</p><p><strong>Methods: </strong>A retrospective analysis was conducted on the clinical data of 92 patients with AML (non APL) admitted to our hospital from January 2018 to May 2022. AML related genes tested were using NGS, the mutation characteristics and survival time of AML patients were analyzed.</p><p><strong>Results: </strong>Among the 92 patients, 41 were males and 51 were females. A total of 38 types of gene mutations were detected. Six-two patients carried at least one gere mutation, while no gene mutations were detected in 30 patients. In the group with favourable prognosis (<i>n</i> =14), the frequencies of higher gene mutations were <i>NRAS, KIT</i> (21.43%, <i>n</i> =3), <i>KRAS</i> (14.29%, <i>n</i> =2). In the group with intermediate prognosis (<i>n</i> =64), the gene mutation frequencies from high to low were <i>DNMT3A</i> (18.75%, <i>n</i> =12), <i>NPM1</i> (17.19%, <i>n</i> =11), <i>IDH2, FLT3-ITD, CEBPA</i> (12.50%, <i>n</i> =8), <i>TET2</i> (10.94%, <i>n</i> =7). In the poor prognosis group (<i>n</i> =14), <i>ASXL1, TP53, EZH2, NRAS</i> had higher gene mutation frequency than others(14.29 %, <i>n</i> =2 ). Statistical analysis revealed that <i>KIT</i> had a relative hotspot of mutations in the intermediate-risk group, and <i>DNMT3A</i> had a relative hotspot of mutations in the high-risk group (<i>P</i> < 0.05). The correlation analysis of genes with high mutation rates in different prognostic groups, such as <i>NRAS, KIT, IDH2, DNMT3A, NPM1</i>, and <i>FLT3-ITD</i>, with prognosis found that <i>KIT</i> was a factor affecting OS (<i>P</i> < 0.05), while no significant differences were observed for the others(<i>P</i> >0.05).</p><p><strong>Conclusion: </strong>The frequency of gene mutations is high in AML patients, 67.4% of the patients carried at least one gene mutation. The mutation frequency varies among different genes in patients with different karyotypes, and there are obvious dominant mutations. <i>KIT</i> and <i>DNMT3A</i> can be used as factors for evaluating the prognosis of AML.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"33 3","pages":"691-697"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144561390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Interaction between COVID-19 Infection and Hematological Malignancies --Review].","authors":"Zi-Heng Wang, Jia-Yi Zhao, Xiao-Feng Shi","doi":"10.19746/j.cnki.issn.1009-2137.2025.03.046","DOIUrl":"https://doi.org/10.19746/j.cnki.issn.1009-2137.2025.03.046","url":null,"abstract":"<p><p>The pandemic of coronavirus disease 2019 (COVID-19) has impacted our lifestyles. On the one hand, the patients with hematological malignancies (HM) are more vulnerable to COVID-19 infection. Once infected with COVID-19, these patients tend to develop into severe type with a higher mortality rate. Although patients with HM demonstrated a reduced response to COVID-19 vaccines, they still can benefit from vaccine injection with reduced rates of viral infection and incidence of severe cases. The combination of monoclonal antibodies and antiviral drugs is helpful to the COVID-19 treatment of patients with HM. On the other hand, COVID-19 infection can lead to a delay of hematopoietic recovery and low immunity in patients with HM. For HM patients with COVID-19 infection, to reduce the intensity and shorten the course of radiotherapy and chemotherapy is needed. This article will review the interaction between COVID-19 infection and HM.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"33 3","pages":"922-926"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144561392","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Recent Advances in Research on the Relationship between Gut Microbiota, Its Metabolites, and Acute Myeloid Leukemia--Review].","authors":"Lei-Lei Kong, Jian Li","doi":"10.19746/j.cnki.issn.1009-2137.2025.03.044","DOIUrl":"https://doi.org/10.19746/j.cnki.issn.1009-2137.2025.03.044","url":null,"abstract":"<p><p>Gut microbiota and its metabolites are associated with a variety of hematological malignancies, including acute myeloid leukemia (AML). AML patients commonly suffer from imbalances in intestinal homeostasis before and after chemotherapy and allogeneic hematopoietic stem cell transplantation (allo-HSCT). The diversity and abundance of gut microbiota, as well as the levels of metabolites, may be biomarkers for predicting the occurrence of infection and graft-versus-host disease (GVHD) in AML patients. In order to offer a theoretical foundation for optimizing treatment strategies for AML patients, this review summarized the latest research progress on gut microbiota and its metabolites in relation to the occurrence, development, treatment and prognosis of AML.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"33 3","pages":"913-917"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144561399","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Short-Term Efficacy of Low-Dose Venetoclax Combined with CHG Priming Regimen in Patients with AML and High-Risk MDS Ineligible for Intensive Chemotherapy].","authors":"Yu-Ze Yang, Mei Zhou, Ya-Ru Xu, Wen-Yan Xu, Jie Sun, Yuan-Yuan Zhu, Yuan Li, Zhen-Xing Guo","doi":"10.19746/j.cnki.issn.1009-2137.2025.03.006","DOIUrl":"https://doi.org/10.19746/j.cnki.issn.1009-2137.2025.03.006","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the short-term efficacy and safety of low-dose venetoclax combined with CHG (cytarabine+homoharringtonine+G-CSF) priming regimen in patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy.</p><p><strong>Methods: </strong>The data of 14 patients with AML or high-risk MDS admitted to the department of hematology/oncology of the First Hospital of Tsinghua University and 2 cooperative institutions from July 2022 to August 2023 were retrospectively analyzed. All the patients were treated with low-dose venetoclax combined with CHG priming regimen and the early induction (one course) efficacy and adverse reactions were observed.</p><p><strong>Results: </strong>Among the 14 patients, 10 were males and 4 were females, with a median age of 69.5 (46-83) years. After 1 cycle of induction chemotherapy, the complete remission (CR) rate was 64.3% (9/14) and overall response rate (ORR) was 78.6% (11/14). Among the 10 patients with adverse prognosis according to cytogenetics and molecular genetics, the CR rate was 50.0% (5/10), and ORR was 70.0% (7/10). In 7 patients with <i>TP53</i> mutation, the CR rate was 42.9% (3/7) and ORR was 71.4% (5/7). In the 6 patients with complex karyotype, CR rate was 33.3% (2/6) and ORR was 66.7% (4/6). While the CR rate and ORR of 8 non-complex karyotype patients were both 87.5% (7/8), and the difference in CR rate between patients with complex karyotype and non-complex karyotype was statistically significant ( <i>P</i> < 0.05). The adverse reactions of chemotherapy were tolerable, without early treatment-related deaths.</p><p><strong>Conclusion: </strong>Low-dose venetoclax combined with CHG priming regimen can be used as an effective treatment for AML and high-risk MDS patients who are ineligible for intensive chemotherapy, and it is safe and worthy of clinical application.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"33 3","pages":"660-665"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144561417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Transcriptomics and Metabolomics Analysis to Explore the Ferroptosis Susceptibility of Venetoclax-Resistant AML Cells].","authors":"Yue Li, Jia-Qi Wan, Xin-Tong Yang, Bao-Quan Song, Fei Li, Hong-Wei Peng","doi":"10.19746/j.cnki.issn.1009-2137.2025.03.001","DOIUrl":"https://doi.org/10.19746/j.cnki.issn.1009-2137.2025.03.001","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the susceptibility of venetoclax-resistant acute myeloid leukemia (AML) cell lines to ferroptosis and to uncover the underlying molecular mechanisms using transcriptomic and metabolomic analysis methods.</p><p><strong>Methods: </strong>Venetoclax-resistant AML cell lines were constructed using a low-dose concentration escalation method. The sensitivity of cells to chemotherapeutic drugs was detected by CCK-8 assay. The susceptibility of drug-resistant cell lines to ferroptosis was assessed using transcriptomic and metabolomic analysis methods. The expression of cellular GPX4 and SLC7A11 protein was detected by Western blot, and cell death and lipid peroxidation levels were measured by flow cytometry. Depmap database and TCGA cohort were applied to explore the effect of ferroptosis-related genes expression on prognosis.</p><p><strong>Results: </strong>Venetoclax-resistant cell lines exhibited sensitivity to ferroptosis inducers RSL3, APR246, and sorafenib. The ferroptosis inhibitor Fer-1 partially inhibited cell death induced by these inducers. Compared with the parental cells, significant changes in metabolites and gene expression levels related to ferroptosis were observed in the resistant cell lines. In particular, deregulated expression of <i>SLC7A11</i> and <i>GPX4</i> may play critical role in ferroptosis susceptibility. Besides, <i>GPX4</i> was identified as more important for AML cell survival and higher <i>GPX4</i> expression may predict shortened overall survival, <i>NPM1</i> mutant and <i>IDH1 R132</i> mutation positive patients may prone to possess higher <i>GPX4</i> expression.</p><p><strong>Conclusion: </strong>Venetoclax-resistant AML cell lines remain susceptible to ferroptosis, higher <i>GPX4</i> expression maybe a critical marker for poor prognosis. Regulating the expression of ferroptosis-related genes and metabolites may enhance the efficacy of venetoclax and provide new treatment options for AML patients.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"33 3","pages":"621-632"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144561424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[A Retrospective Clinical Analysis of Multiple Myeloma Patients with Cardiac Amyloidosis].","authors":"Tian-Yue Bian, Shun Wang, Qun Lu, Shi-Hui Yuan, Rui Li, Rui Xu, Ying Chen, Hua-Sheng Liu","doi":"10.19746/j.cnki.issn.1009-2137.2025.03.031","DOIUrl":"https://doi.org/10.19746/j.cnki.issn.1009-2137.2025.03.031","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the clinical characteristics, curative effect and prognostic factors of patients with multiple myeloma (MM) complicated with light chain myocardial amyloidosis (AL-CA).</p><p><strong>Methods: </strong>The data of 38 patients diagnosed with MM complicated with AL-CA in our hospital from January 2018 to December 2023 were retrospectively analyzed, and the data were comprehensively screened by multiple methods such as positive two-dimensional spot tracking echocardiography (2D-STE). Survival analysis was performed using the Kaplan-Meier method. Cox regression models were used to screen for independent prognostic factors.</p><p><strong>Results: </strong>Among the 38 MM patients with AL-CA, 23 were male and 15 were female, with a median age of 60(50,75) years. The 1-year survival rate was 71.05%. Patients who underwent transplantation had significantly better survival outcomes than those who did not (<i>P</i> < 0.01). Additionally, the median survival time of patients with all-negative FISH results at the first visit was statistically different compared to patients with other mutations (<i>P</i> < 0.05). Multivariate Cox regression analysis showed that all negative FISH results at the first visit and the absence of autologous hematopoietic stem cell transplantation (ASCT) were not independent risk factor for the prognosis of patients with MM and AL-CA (<i>P</i> >0.05).</p><p><strong>Conclusion: </strong>ASCT may improve the prognosis of MM patients with AL-CA, and negative FISH results may indicate poor prognosis, but the results still need to be verified by larger samples.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"33 3","pages":"834-840"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144561363","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Efficacy of Blinatumomab in the Treatment of Pediatric B-cell Acute Lymphoblastic Leukemia].","authors":"Jian Wang, Ya-Ting Zhang, Kai-Mei Wang, Jian-Pei Fang, Dun-Hua Zhou","doi":"10.19746/j.cnki.issn.1009-2137.2025.03.011","DOIUrl":"https://doi.org/10.19746/j.cnki.issn.1009-2137.2025.03.011","url":null,"abstract":"<p><strong>Objective: </strong>To retrospectively analyze the clinical characteristics of 15 children with B-cell acute lymphoblastic leukemia (B-ALL) treated with blinatumomab, and summarize the efficacy and safety of blinatumomab in the treatment of pediatric B-ALL.</p><p><strong>Methods: </strong>Fifteen children who received treatment with blinatumomab from February 2022 to January 2023 were enrolled in this study. One course (28 days) of blinatumomab concurrent with intrathecal chemotherapy was given according to the standard regimen, except for 2 cases who had shortened course of treatment due to hematopoietic stem cell transplantation (HSCT) and did not receive combined intrathecal chemotherapy, and 1 case had a shortened course of treatment due to economic problems. The efficacy and safety of the treatment were evaluated.</p><p><strong>Results: </strong>In terms of efficacy, for the children who had achieved complete molecular remission (CMR) before treatment, blinatumomab treatment could effectively maintain CMR status; For the children who did not achieve CMR, the CMR rate after one standard course of treatment with blinatumomab reached 66.7%(4/6); For the children with relapsed/refractory ALL (R/R ALL) who had minimal residual disease (MRD), the MRD clearance rate reached 75.0%(3/4). The statistical results of the incidence of adverse events showed that 13.3%(2/15) of the children did not experience any adverse events. The most common adverse events were cytokine release syndrome (CRS) (73.3%, 11/15) and transaminase elevation (26.7%, 4/15); 33.3%(5/15) of the children experienced grade 3 or higher adverse events. All the adverse events were resolved after symptomatic treatment.The level of IgG decreased significantly after 4-7 weeks of treatment with blinatumomab, and gradually recovered after 8 weeks of treatment.</p><p><strong>Conclusion: </strong>Blinatumomab can be used as a safe and effective treatment for inducing deep remission in pediatric R/R-ALL patients and as a bridge therapy for the pediatric ALL patients who are intolerant to chemotherapy.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"33 3","pages":"698-705"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144561385","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Retrospective Analysis of Venetoclax Combined with Azacitidine Compared with \"3+7\" or Similar Regimens for Newly Diagnosed Patients with Acute Myeloid Leukemia].","authors":"Lu-Lu Wang, Juan Zhang, Yue Zhang, Yong Zhang, Xiao-Min Dong, Dan-Yang Zhang, Ting-Ting Chen, Yun-Hui Zhou, Teng Wang, Hui-Ling Lan, He-Bing Zhou","doi":"10.19746/j.cnki.issn.1009-2137.2025.03.008","DOIUrl":"https://doi.org/10.19746/j.cnki.issn.1009-2137.2025.03.008","url":null,"abstract":"<p><strong>Objective: </strong>To retrospectively analyze the clinical data of newly diagnosed acute myeloid leukemia (AML) patients treated with venetoclax combined with azacitidine (Ven/Aza) or standard \"3+7\" regimen and similar regimens, collect real-world study data, compare the treatment response and adverse events between the two regimens, as well as perform survival analysis.</p><p><strong>Methods: </strong>To retrospectively analyze the efficacy, survival, and adverse reactions of newly diagnosed AML patients treated with Ven/Aza (24 cases) and \"3+7\" regimens (117 cases ) in our hospital from September 2009 to March 2023, as well as factors influencing outcomes. A propensity score matching (PSM) was performed on age and Eastern Cooperative Oncology Group performance status (ECOG PS) to obtain a 1:1 matched cohort of 20 pairs, and the efficacy and survival before and after the matching were compared.</p><p><strong>Results: </strong>The median age of patients in the Ven/Aza group was 69 years, while that in the \"3+7\" group was 56 years (<i>P</i> <0.001). Objective remission rate (ORR) was 62.5% in Ven/Aza group and 74.8% in \"3+7\" group (<i>P</i> >0.05). The median overall survival (OS) in the Ven/Aza group was 522 days, while that in the \"3+7\" group was 1 002 days (<i>P</i> >0.05). After controlling the two variables of age and ECOG PS, a PSM cohort of 20 pairs was obtained, in which the ORR was 65% in Ven/Aza group and 60% in \"3+7\" group (<i>P</i> >0.05). The median OS was 522 days and 629 days, and median progression-free survival (PFS) was 531 days and 198 days between the two groups, respectively. There were no statistically significant differences in OS and PFS between the two groups (both <i>P</i> >0.05). Additionally, the incidence of adverse events in the Ven/Aza group was significantly reduced.</p><p><strong>Conclusion: </strong>The overall cohort shows that the \"3+7\" regimen has advantages in efficacy and survival, but Ven/Aza regimen is relatively safer. After performing PSM on age and ECOG PS, the Ven/Aza group showed improved efficacy, and a longer median PFS compared to \"3+7\" group.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"33 3","pages":"672-681"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144561403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[The Efficacy and Safety of Daratumumab-Based Combination Therapy in Multiple Myeloma].","authors":"Fan Gao, Yu-Lan Zhou, Shi-Xuan Wang, Hui-Min Shen, Min Yu, Fei Li","doi":"10.19746/j.cnki.issn.1009-2137.2025.03.027","DOIUrl":"https://doi.org/10.19746/j.cnki.issn.1009-2137.2025.03.027","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the efficacy and safety of combination regimen containing daratumumab in multiple myeloma (MM) patients.</p><p><strong>Methods: </strong>The clinical data of 14 newly diagnosed MM patients and 58 relapsed refractory MM patients treated with combination regimen containing daratumumab from November 2020 to March 2023 in the First Affiliated Hospital of Nanchang University were retrospectively analyzed. The efficacy and safety of combination regimen were analyzed.</p><p><strong>Results: </strong>The median age of the 72 patients was 62 (38-78) years, including 35 males and 37 females. The overall response rate (ORR) of patients receiving first-line, second-line, and third-line or above treatment was 92.9% (13/14), 68.2% (30/44), and 42.9% (6/14), respectively. The median progression-free survival (PFS) was not reached, 15.4 months, and 9.7 months in three groups, respectively (all <i>P</i> <0.05), while the median overall survival (OS) was all not reached. Among relapsed refractory patients, the ORR of those treated with DVd, DPd and DRd regimen was 50.0% (12/24), 40.0% (4/10) and 100% (10/10), the median PFS was 2.8 months, 10.3 months and not reached, and the median OS was 15.4 months, not reached and not reached, respectively. Furthermore, the PFS and OS in the DRd group were superior to those in the other two groups (all <i>P</i> <0.05). Cox univariate and multivariate analysis showed that lactate dehydrogenase (LDH) ≥250 U/L and extramedullary disease were independent adverse prognostic factors for PFS, and LDH ≥250 U/L was also an independent adverse prognostic factor for OS. Hematologic adverse reactions were mainly lymphopenia (87.5%) and thrombocytopenia (52.8%), while non-hematologic adverse reactions were mainly infusion-related reactions (19.4%) and infections (11.1%).</p><p><strong>Conclusions: </strong>The combination regimens containing daratumumab can be used as first-line treatment for patients with newly diagnosed MM. In patients with relapsed refractory MM, early use of regimens containing daratumumab may improve treatment response rate and prolong PFS. The DRd regimen has better therapeutic response and survival advantages. LDH is an independent prognostic factor affecting PFS and OS in MM patients.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"33 3","pages":"810-815"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144561420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Effect of Daratumumab, Lenalidomide, and Dexamethasone on Quality of Life in Patients with Newly Diagnosed Multiple Myeloma Ineligible for Stem Cell Transplantation].","authors":"Zhi-Hui Li, Jin-Hui Wang, Meng-Meng Liu, Peng-Tao Xing, Yan-Ping Zhang, Xin-Rong Zhan","doi":"10.19746/j.cnki.issn.1009-2137.2025.03.028","DOIUrl":"https://doi.org/10.19746/j.cnki.issn.1009-2137.2025.03.028","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the effect of daratumumab, lenalidomide and dexamethasone on quality of life in transplant-ineligible (TIE) patients with newly diagnosed multiple myeloma (NDMM).</p><p><strong>Methods: </strong>The clinical data of 93 TIE NDMM patients in our hospital from January 2020 to December 2022 were retrospectively analyzed. The patients were divided into D-Rd group (48 cases) and Rd group (45 cases) according to treatment regimen. The patients in Rd group were treated with lenalidomide and dexamethasone, while those in D-Rd group were treated with daratumumab on the basis of Rd group. The QLQ-C30 and EQ-5D VAS scores of the two groups were compared at baseline and after 3, 6 and 12 treatment cycles. The last follow-up date was June 30, 2023, and overall survival (OS) was compared between the two groups.</p><p><strong>Results: </strong>The median follow-up period in the D-Rd group was 21 (7-38) months, and the median OS was 34 months, while that in the Rd group was 16 (5-35) months, and the median OS was 28 months. There was significant difference in OS between the two groups ( <i>P</i> <0.05). After 3, 6 and 12 treatment cycles, the QLQ-C30 score and EQ-5D VAS score of the two groups were significantly improved (all <i>P</i> <0.05). After 3 and 12 treatment cycles, the QLQ-C30 score and EQ-5D VAS score of D-Rd group were significantly higher than those of Rd group (all <i>P</i> <0.05). There were no significant differences in the improvement of QLQ-C30 GHS and pain scores between the two groups of patients with age <75 years and ECOG 0-1 score after 3, 6 and 12 treatment cycles (<i>P</i> >0.05). In D-Rd group of patients with age≥75 years, the improvement of QLQ-C30 GHS scores after 3 and 12 treatment cycles and QLQ-C30 pain scores after 3, 6 and 12 treatment cycles was significantly superior to that in Rd group (all <i>P</i> <0.05). In D-Rd group of patients with ECOG 2 scores, the improvement of QLQ-C30 GHS and pain scores after 3, 6 and 12 treatment cycles was significantly superior to that in Rd group (all <i>P</i> <0.05).</p><p><strong>Conclusion: </strong>Daratumumab, lenalidomide, and dexamethasone can significantly improve OS in TIE NDMM patients without decrease of quality of life, especially in those with age≥75 years or ECOG 2 scores.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"33 3","pages":"816-821"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144561383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}